These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1640 related articles for article (PubMed ID: 31466926)

  • 21. A second-generation CD38-CAR-T cell for the treatment of multiple myeloma.
    Li H; Li J; Wu J; Shi Z; Gao Y; Song W; Li J; Li Z; Zhang M
    Cancer Med; 2023 May; 12(9):10804-10815. PubMed ID: 37039305
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human GUCY2C-Targeted Chimeric Antigen Receptor (CAR)-Expressing T Cells Eliminate Colorectal Cancer Metastases.
    Magee MS; Abraham TS; Baybutt TR; Flickinger JC; Ridge NA; Marszalowicz GP; Prajapati P; Hersperger AR; Waldman SA; Snook AE
    Cancer Immunol Res; 2018 May; 6(5):509-516. PubMed ID: 29615399
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of Antitumor Effects of CAR-T Cells in Mice with Solid Tumors.
    Rodriguez-Garcia A; Watanabe K; Guedan S
    Methods Mol Biol; 2020; 2086():251-271. PubMed ID: 31707682
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunobiology of chimeric antigen receptor T cells and novel designs.
    Walsh Z; Yang Y; Kohler ME
    Immunol Rev; 2019 Jul; 290(1):100-113. PubMed ID: 31355496
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overcoming Target Driven Fratricide for T Cell Therapy.
    Breman E; Demoulin B; Agaugué S; Mauën S; Michaux A; Springuel L; Houssa J; Huberty F; Jacques-Hespel C; Marchand C; Marijsse J; Nguyen T; Ramelot N; Violle B; Daro D; De Waele P; Gilham DE; Steenwinckel V
    Front Immunol; 2018; 9():2940. PubMed ID: 30619300
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preclinical Assessment of CAR T-Cell Therapy Targeting the Tumor Antigen 5T4 in Ovarian Cancer.
    Owens GL; Sheard VE; Kalaitsidou M; Blount D; Lad Y; Cheadle EJ; Edmondson RJ; Kooner G; Gilham DE; Harrop R
    J Immunother; 2018 Apr; 41(3):130-140. PubMed ID: 29239915
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined Antitumor Effects of Sorafenib and GPC3-CAR T Cells in Mouse Models of Hepatocellular Carcinoma.
    Wu X; Luo H; Shi B; Di S; Sun R; Su J; Liu Y; Li H; Jiang H; Li Z
    Mol Ther; 2019 Aug; 27(8):1483-1494. PubMed ID: 31078430
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CAR T-cell therapy: Full speed ahead.
    Sermer D; Brentjens R
    Hematol Oncol; 2019 Jun; 37 Suppl 1():95-100. PubMed ID: 31187533
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recent advances in tumor associated carbohydrate antigen based chimeric antigen receptor T cells and bispecific antibodies for anti-cancer immunotherapy.
    Rashidijahanabad Z; Huang X
    Semin Immunol; 2020 Feb; 47():101390. PubMed ID: 31982247
    [TBL] [Abstract][Full Text] [Related]  

  • 30. T cells bearing anti-CD19 and/or anti-CD38 chimeric antigen receptors effectively abrogate primary double-hit lymphoma cells.
    Mihara K; Yoshida T; Takei Y; Sasaki N; Takihara Y; Kuroda J; Ichinohe T
    J Hematol Oncol; 2017 Jun; 10(1):116. PubMed ID: 28595585
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD38-Specific CAR Integrated into CD38 Locus Driven by Different Promoters Causes Distinct Antitumor Activities of T and NK Cells.
    Liao C; Wang Y; Huang Y; Duan Y; Liang Y; Chen J; Jiang J; Shang K; Zhou C; Gu Y; Liu N; Zeng X; Gao X; Tang Y; Sun J
    Adv Sci (Weinh); 2023 Sep; 10(27):e2207394. PubMed ID: 37485647
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
    Gauthier J; Yakoub-Agha I
    Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.
    Kosti P; Maher J; Arnold JN
    Front Immunol; 2018; 9():1104. PubMed ID: 29872437
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multi-Specific CAR Targeting to Prevent Antigen Escape.
    Walsh Z; Ross S; Fry TJ
    Curr Hematol Malig Rep; 2019 Oct; 14(5):451-459. PubMed ID: 31332617
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bispecific CAR T Cells against EpCAM and Inducible ICAM-1 Overcome Antigen Heterogeneity and Generate Superior Antitumor Responses.
    Yang Y; McCloskey JE; Yang H; Puc J; Alcaina Y; Vedvyas Y; Gomez Gallegos AA; Ortiz-Sánchez E; de Stanchina E; Min IM; von Hofe E; Jin MM
    Cancer Immunol Res; 2021 Oct; 9(10):1158-1174. PubMed ID: 34341066
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A CAR RNA FISH assay to study functional and spatial heterogeneity of chimeric antigen receptor T cells in tissue.
    Eichholz K; Li AZ; Diem K; Jensen MC; Zhu J; Corey L
    Sci Rep; 2021 Jun; 11(1):12921. PubMed ID: 34155235
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fourth-generation chimeric antigen receptor T cells targeting folate receptor alpha antigen expressed on breast cancer cells for adoptive T cell therapy.
    Luangwattananun P; Junking M; Sujjitjoon J; Wutti-In Y; Poungvarin N; Thuwajit C; Yenchitsomanus PT
    Breast Cancer Res Treat; 2021 Feb; 186(1):25-36. PubMed ID: 33389403
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analysis of CAR-Mediated Tonic Signaling.
    Calderon H; Mamonkin M; Guedan S
    Methods Mol Biol; 2020; 2086():223-236. PubMed ID: 31707680
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Driving CARs on the uneven road of antigen heterogeneity in solid tumors.
    Chen N; Li X; Chintala NK; Tano ZE; Adusumilli PS
    Curr Opin Immunol; 2018 Apr; 51():103-110. PubMed ID: 29554494
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effective Targeting of TAG72
    Murad JP; Kozlowska AK; Lee HJ; Ramamurthy M; Chang WC; Yazaki P; Colcher D; Shively J; Cristea M; Forman SJ; Priceman SJ
    Front Immunol; 2018; 9():2268. PubMed ID: 30510550
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 82.